GTCR announced it has completed the acquisition of Zentiva from Advent International, marking a significant expansion of its healthcare investment portfolio.
Zentiva is a leading developer, manufacturer, and supplier of generic, branded specialty, and over-the-counter medicines, serving more than 100 million people across over 40 countries. The company brings established research and development capabilities and a strong reputation for clinical quality and product reliability.
GTCR will partner with Zentiva’s leadership team, including Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to drive the company’s next phase of growth. The firm plans to invest in product development, expand the company’s portfolio, and broaden its geographic reach to enhance access to affordable medicines across Europe.
The acquisition aligns with GTCR’s long-standing focus on healthcare investments and reflects growing demand for cost-effective pharmaceutical solutions amid increasing pressure on global healthcare systems. Zentiva’s scale, manufacturing capabilities, and regional footprint position it to play a key role in improving access to essential medicines while supporting sustainable healthcare delivery.
Advisors on the transaction included Barclays, BNP Paribas, Morgan Stanley, and Kirkland & Ellis for GTCR, and Goldman Sachs, PJT Partners, and Freshfields for Advent International.
KEY QUOTES:
“We are proud of Zentiva’s strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth. With GTCR’s support and significant industry expertise, we believe we are ideally placed to accelerate our momentum and continue our mission of expanding access to high quality, affordable medicines to millions of people across Europe.”
Steffen Saltofte, Chief Executive Officer, Zentiva
“We are excited to partner with Steffen and the Zentiva team to further the Company’s success. As policymakers increasingly prioritize expanding access to essential medicines while ensuring long term sustainability of healthcare systems, Zentiva plays a critical role in delivering high quality, cost effective therapies at scale. Combined with its differentiated geographic footprint and low cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long term growth and impact.”
Sean Cunningham, Managing Director And Head Of Healthcare, GTCR
“We are immensely proud of the business Zentiva has become during our partnership, a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines. We would like to thank Steffen and all the talented Zentiva team members who played a part in the company’s transformation. We look forward to watching Zentiva go from strength to strength in the years ahead.”
Tom Allen, Managing Director, Advent International
